Tweet
Clin Exp Immunol. 2014 Feb 15. doi: 10.1111/cei.12292. [Epub ahead of print]
Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.
Milanetti F1, Germano V, Nisini R, Donatelli I, Martino A, Facchini M, Ferlito C, Cappella A, Crialesi D, Caporuscio S, Biselli R, Rossi F, Salemi S, D'Amelio R.
Author information
Abstract
Rheumatoid Arthritis (RA) patients under immunosuppressive therapy are particularly susceptible to infections, mainly of the respiratory tract, thus vaccination may represent a strategy to reduce their incidence in this vulnerable population. In the 2009-2010 influenza season, safety and immunogenicity of co-administered non-adjuvanted seasonal and MF59-adjuvanted pandemic influenza vaccines were, therefore, here evaluated in 30 RA patients under therapy with anti-tumor necrosis (TNF) factor-α agents or Abatacept and in 13 healthy controls (HC). Patients and HC underwent clinical and laboratory evaluation before (T0), one (T1) and six months (T2) after vaccinations. No severe adverse reactions, but a significant increase in total mild side effects in patients versus HC were observed. Both influenza vaccines fulfilled the three criteria of the Committee for Human Medicinal Products (CHMP). Seroconversion rate for any viral strain in patients and HC was respectively: 68 versus 45 for H1-A/Brisbane/59/07, 72 versus 81 for H3-A/Brisbane/10/07, 68 versus 54 for B/Brisbane/60/08 and 81 versus 54 for A/California/7/2009. A slight increase in activated IFNγ-, TNFα- or IL17A-secreting T-cells at T1 compared to T0, followed by a reduction at T2 in both patients and HC, was registered. In conclusion, simultaneous administration of adjuvanted pandemic and non-adjuvanted seasonal influenza vaccines is safe and highly immunogenic. The largely overlapping results between patients and HC, in terms of antibody response and cytokine-producing T-cells, may represent a further evidence for vaccine safety and immunogenicity in RA patients on biologicals.
This article is protected by copyright. All rights reserved.
KEYWORDS:
T cells, rheumatoid arthritis, vaccination
PMID:
24666311
[PubMed - as supplied by publisher]
Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.
Milanetti F1, Germano V, Nisini R, Donatelli I, Martino A, Facchini M, Ferlito C, Cappella A, Crialesi D, Caporuscio S, Biselli R, Rossi F, Salemi S, D'Amelio R.
Author information
Abstract
Rheumatoid Arthritis (RA) patients under immunosuppressive therapy are particularly susceptible to infections, mainly of the respiratory tract, thus vaccination may represent a strategy to reduce their incidence in this vulnerable population. In the 2009-2010 influenza season, safety and immunogenicity of co-administered non-adjuvanted seasonal and MF59-adjuvanted pandemic influenza vaccines were, therefore, here evaluated in 30 RA patients under therapy with anti-tumor necrosis (TNF) factor-α agents or Abatacept and in 13 healthy controls (HC). Patients and HC underwent clinical and laboratory evaluation before (T0), one (T1) and six months (T2) after vaccinations. No severe adverse reactions, but a significant increase in total mild side effects in patients versus HC were observed. Both influenza vaccines fulfilled the three criteria of the Committee for Human Medicinal Products (CHMP). Seroconversion rate for any viral strain in patients and HC was respectively: 68 versus 45 for H1-A/Brisbane/59/07, 72 versus 81 for H3-A/Brisbane/10/07, 68 versus 54 for B/Brisbane/60/08 and 81 versus 54 for A/California/7/2009. A slight increase in activated IFNγ-, TNFα- or IL17A-secreting T-cells at T1 compared to T0, followed by a reduction at T2 in both patients and HC, was registered. In conclusion, simultaneous administration of adjuvanted pandemic and non-adjuvanted seasonal influenza vaccines is safe and highly immunogenic. The largely overlapping results between patients and HC, in terms of antibody response and cytokine-producing T-cells, may represent a further evidence for vaccine safety and immunogenicity in RA patients on biologicals.
This article is protected by copyright. All rights reserved.
KEYWORDS:
T cells, rheumatoid arthritis, vaccination
PMID:
24666311
[PubMed - as supplied by publisher]
